Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).
about
Burden of Mycobacterium ulcerans disease (Buruli ulcer) and the underreporting ratio in the territory of Songololo, Democratic Republic of CongoRapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infectionLong term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial.Experimental infection of the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease.Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?Proteomic analysis of the action of the Mycobacterium ulcerans toxin mycolactone: targeting host cells cytoskeleton and collagen.Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?Contribution of the community health volunteers in the control of Buruli ulcer in Bénin.Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy--a case report from Togo.Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.Implementation of a national reference laboratory for Buruli ulcer disease in Togo.The use of ozone therapy in Buruli ulcer had an excellent outcome.Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad modelEstablishment of quantitative PCR (qPCR) and culture laboratory facilities in a field hospital in benin: 1-year results.Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review.Multicenter external quality assessment program for PCR detection of Mycobacterium ulcerans in clinical and environmental specimensTreating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infectionTreatment Outcome of Patients with Buruli Ulcer Disease in Togo.A Genomic Approach to Resolving Relapse versus Reinfection among Four Cases of Buruli Ulcer.Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli UlcerLocal Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single Center Non Comparative Clinical Trial.Buruli ulcer in Nigeria: results of a pilot case study in three rural districts.Epidemiology and management of Buruli ulcer.Bacterial diversity in Buruli ulcer skin lesions: Challenges in the clinical microbiome analysis of a skin diseaseParadoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection.Improving clinical and epidemiological predictors of Buruli ulcer
P2860
Q21090118-F1A17C98-40CD-4B94-8F65-CBC95B8A500DQ28537749-3F14A58F-4CCB-4E00-9A80-7A3C30E54078Q28540814-8F5F7570-2717-47FD-8FA8-3629E8AD3995Q33881961-1790AC68-5FB3-46EE-88D4-E65B21F692E1Q33988898-1977B56F-B5B7-447E-91F3-572A4B9824C1Q34016179-7B71903D-5084-4216-AE94-29C7395B1B12Q34043539-FD59CD24-38F9-43A6-AD5F-E68162D6827EQ34281971-23257E40-4C08-4D60-A1F3-549A834F43B2Q34364979-686EA74E-25CB-4707-A70C-DE56E0B9E143Q34483614-FCF39FAC-8BF8-4009-B078-70DD3E2C3604Q34500901-08BE44D0-BFF8-46BA-B76E-AD071B1ECA35Q34566632-4E2B537C-8AEE-4904-81B8-5B103DEE4E31Q34647915-16DFF811-86B5-432E-ACBC-C75BA56DB6D0Q34702499-3F9563EB-A195-4C15-ADCB-D2604507839AQ35036322-23CE6832-1E9E-4D76-A18A-9C7608E3979AQ35084312-E0960515-A709-497B-882C-41A697389C77Q35107244-78B8B4CE-C3DA-4D1F-A650-D4211D722E74Q35625819-8436CB8C-2CB0-4F30-92B9-08DD2A5ED6F9Q35689285-1D04AF98-5E27-444E-B392-C9683481F9C2Q35790836-B148CEDC-0D14-4BBC-A993-9A2641295B56Q35810457-7DBC2B2A-96CE-41F1-8070-104C20BD2381Q35855507-74072B07-39BB-4C7B-91CE-69F46509D762Q35994923-21CFA71E-13DD-403A-BA40-F9043873F791Q36446126-F06E0A39-F63E-477C-803B-0D901485914EQ36828007-071BFB9B-476B-42DF-990D-0E3751AC2854Q38219419-536965B9-8C76-487A-973E-1DD88B4E1409Q39551255-88F70A87-1B67-4474-9807-950FAEC62C16Q40011360-7ECD1CD0-0E1A-46D4-B337-02D188081F46Q58798763-BBA56E0B-AF5F-45CA-954F-B75996475F0A
P2860
Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Response to treatment in a pro ...... cobacterium ulcerans disease).
@ast
Response to treatment in a pro ...... cobacterium ulcerans disease).
@en
type
label
Response to treatment in a pro ...... cobacterium ulcerans disease).
@ast
Response to treatment in a pro ...... cobacterium ulcerans disease).
@en
prefLabel
Response to treatment in a pro ...... cobacterium ulcerans disease).
@ast
Response to treatment in a pro ...... cobacterium ulcerans disease).
@en
P2093
P2860
P50
P1476
Response to treatment in a pro ...... cobacterium ulcerans disease).
@en
P2093
Françoise Portaels
Jean-Baptiste Mputu-Yamba
Jean-Bedel Minuku
Jean-Jacques Roux
Kapay Kibadi
Makanzu Kayinua
Wayne M Meyers
P2860
P356
10.1371/JOURNAL.PNTD.0000736
P407
P577
2010-07-06T00:00:00Z